tailieunhanh - Adjuvant stereotactic fractionated radiotherapy to the resection cavity in recurrent glioblastoma – the GlioCave study (NOA 17 – ARO 2016/3 – DKTK ROG trial)

Glioblastoma relapses in the vast majority of cases within 1 year. Maximum safe resection of the recurrent glioblastoma can be offered in some cases. Re-irradiation has been established for the treatment of recurrent glioblastoma, too. In both cases, adjuvant treatment, mostly using temozolomide, can improve PFS and OS after these interventions. | Adjuvant stereotactic fractionated radiotherapy to the resection cavity in recurrent glioblastoma the GlioCave study NOA 17 ARO 2016 3 DKTK ROG trial

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN